Kidney involvement in hereditary transthyretin amyloidosis: a cohort study of 103 patients - Aix-Marseille Université Access content directly
Journal Articles Clinical Kidney Journal Year : 2022

Kidney involvement in hereditary transthyretin amyloidosis: a cohort study of 103 patients

Abstract

Background: hereditary transthyretin amyloidosis (ATTRv) is a disabling and life-threatening disease that primarily affects the nervous system and heart. Its kidney involvement has not been systematically studied, particularly in non-V30M mutations, and is not well known to nephrologists. Methods: we conducted a retrospective study describing the kidney phenotype of all prevalent patients with ATTR mutations, with neurological or cardiac involvement or presymptomatic carriers, followed up in two university hospitals from the South of France between June 2011 and June 2021. Results: a total of 103 patients were included, among whom 79 were symptomatic and 24 were presymptomatic carriers. Patients carried 21 different ATTR mutations and 54% carried the V30M mutation. After a mean follow-up of 7.9 ± 25.7 years, 30.4% of the symptomatic patients had developed chronic kidney disease (CKD) and 20.3% had a urinary protein:creatinine ratio ≥0.5 g/g. None of the presymptomatic carriers had CKD or proteinuria. In a multivariate analysis, late onset of symptoms (after 60 years), the V122I mutation and proteinuria were significantly associated with CKD. The median CKD-free survival in symptomatic patients was estimated at 81.0 years (interquartile range 77.1–84.9). It did not differ between V30M and non-V30M patients, but was lower in patients with the V122I mutation. The average age of the onset of CKD was 69.3 ± 13.0 years. In one 38-year-old V30M female who presented a kidney-predominant phenotype, treatment with patisiran resulted in remission of the nephrotic syndrome. Conclusion: CKD affects almost one-third of patients with symptomatic ATTRv. The role of ATTRv per se in the development of CKD in this population remains to be determined, but some patients may benefit from specific therapies.
Fichier principal
Vignette du fichier
sfac118.pdf (694.46 Ko) Télécharger le fichier
Origin : Publisher files allowed on an open archive
Licence : CC BY NC - Attribution - NonCommercial

Dates and versions

hal-03780364 , version 1 (02-03-2023)

Licence

Attribution - NonCommercial

Identifiers

Cite

Justine Solignac, Emilien Delmont, Etienne Fortanier, Shahram Attarian, Julien Mancini, et al.. Kidney involvement in hereditary transthyretin amyloidosis: a cohort study of 103 patients. Clinical Kidney Journal, 2022, 15 (9), pp.1747-1754. ⟨10.1093/ckj/sfac118⟩. ⟨hal-03780364⟩
27 View
42 Download

Altmetric

Share

Gmail Facebook X LinkedIn More